Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAk, Dilek
dc.contributor.authorTöre, F
dc.contributor.authorTuncel, N
dc.date.accessioned2019-10-19T14:02:46Z
dc.date.available2019-10-19T14:02:46Z
dc.date.issued2004
dc.identifier.issn1381-6128
dc.identifier.issn1873-4286
dc.identifier.urihttps://dx.doi.org/10.2174/1381612043384934
dc.identifier.urihttps://hdl.handle.net/11421/12380
dc.descriptionWOS: 000221066100004en_US
dc.descriptionPubMed ID: 15134484en_US
dc.description.abstractIn recent years, VIP/PACAP/secretin family has special interest. Family members are vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, glucagon, glucagon like peptide-1 (GLP(1)), GLP(2), gastric inhibitory peptide (GIP), growth hormone releasing hormone (GHRH or GRF), and peptide histidine methionine (PHM). Most of the family members present both in central nervous system (CNS) and ill various peripheral tissues. The family members that are released into blood from periphery, especially gut, circulate the brain and they can cross the blood brain barrier. Oil the other hand, some of the members of this family that present in the brain, call cross from brain to blood and reach the peripheral tat-gets. VIP, secretin, GLP(1), and PACAP 27 are transported into the brain by transmembrane diffusion, a non-saturable mechanism. However, uptake of PACAP 38 into the brain is saturable mechanism. While there is no report for the passage of GIP, GLP(2) and PHM, there is only one report that shows, glucagon and GHRH can cross the BBB. The passage of VIP/PACAP/secretin family members opens up new horizon for understanding of CNS effects of peripherally administrated peptides. There is much hope that those peptides may prove to be useful in the treatment of serious neurological diseases such as Alzheimer's disease, amyotropic lateral sclerosis, Parkinson's disease, AIDS related neuropathy, diabetic neuropathy, autism, stroke and nerve injury. Their benefits ill various pathophysiologic conditions undoubtly motivate the development of a novel drug design for future therapeutics.en_US
dc.language.isoengen_US
dc.publisherBentham Science Publ LTDen_US
dc.relation.isversionof10.2174/1381612043384934en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePassage of VIP/PACAP/secretin family across the blood-brain barrier: Therapeutic effectsen_US
dc.typereviewen_US
dc.relation.journalCurrent Pharmaceutical Designen_US
dc.contributor.departmentAnadolu Üniversitesi, Eczacılık Fakültesi, Analitik Kimya Anabilim Dalıen_US
dc.identifier.volume10en_US
dc.identifier.issue12en_US
dc.identifier.startpage1325en_US
dc.identifier.endpage1340en_US
dc.relation.publicationcategoryDiğeren_US
dc.contributor.institutionauthorAk, Dilek


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster